Evofem Strengthens Phexxi Intellectual Property With New Composition of Matter Patent From USPTO

-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in the U

PR NewswireApr 18 08:36 ET

Evofem Biosciences Issues Update With Latest Presentation

TipRanksMar 28 17:22 ET

Evofem Biosciences 4Q Loss/Shr 44c >EVFM

Evofem Biosciences 4Q Loss/Shr 44c >EVFM

Dow JonesMar 27 08:36 ET

Evofem Reports $18.2 Million of Phexxi Net Product Sales in 2023

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth q

PR NewswireMar 27 08:36 ET

Press Release: Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI With Medi-Cal

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal PR Newswire SAN DIEGO, March 20, 2024 -- Medi-Cal serves more than 15.4 million Californians --

Dow JonesMar 20 08:54 ET

For Women Using GLP-1 Receptor Agonists Who Take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel Is a Logical Solution to Help Prevent Unintended Pregnancy

Yahoo FinanceMar 7 07:54 ET